CN110753546B - 治疗或预防急性肺损伤的化合物、组合物和方法 - Google Patents

治疗或预防急性肺损伤的化合物、组合物和方法 Download PDF

Info

Publication number
CN110753546B
CN110753546B CN201880039957.3A CN201880039957A CN110753546B CN 110753546 B CN110753546 B CN 110753546B CN 201880039957 A CN201880039957 A CN 201880039957A CN 110753546 B CN110753546 B CN 110753546B
Authority
CN
China
Prior art keywords
pazopanib
salt
subject
administration
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880039957.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110753546A (zh
Inventor
D·吴
Q·袁
A·巴希特
W·唐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of CN110753546A publication Critical patent/CN110753546A/zh
Application granted granted Critical
Publication of CN110753546B publication Critical patent/CN110753546B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201880039957.3A 2017-04-17 2018-04-17 治疗或预防急性肺损伤的化合物、组合物和方法 Active CN110753546B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762486232P 2017-04-17 2017-04-17
US62/486,232 2017-04-17
PCT/US2018/027980 WO2018195084A1 (en) 2017-04-17 2018-04-17 Compounds, compositions and methods of treating or preventing acute lung injury

Publications (2)

Publication Number Publication Date
CN110753546A CN110753546A (zh) 2020-02-04
CN110753546B true CN110753546B (zh) 2023-11-10

Family

ID=63856399

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880039957.3A Active CN110753546B (zh) 2017-04-17 2018-04-17 治疗或预防急性肺损伤的化合物、组合物和方法

Country Status (7)

Country Link
US (3) US11166953B2 (https=)
EP (1) EP3612184B1 (https=)
JP (1) JP7108018B2 (https=)
CN (1) CN110753546B (https=)
CA (1) CA3060247A1 (https=)
IL (1) IL270070B2 (https=)
WO (1) WO2018195084A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7108018B2 (ja) 2017-04-17 2022-07-27 イエール ユニバーシティ 急性肺傷害を処置または予防する化合物、組成物および方法
JP2023502252A (ja) * 2019-11-20 2023-01-23 イエール ユニバーシティ 虚血再灌流傷害および／または肺傷害を処置するための化合物、組成物および方法
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
CA3179187A1 (en) * 2020-05-22 2021-11-25 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with viral infections
CN113624978B (zh) * 2021-04-06 2023-09-19 四川大学华西医院 通过检测肺泡灌洗液及血清白蛋白来评估急性呼吸窘迫综合征/急性肺损伤及预后的试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142837A1 (en) * 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
CN102869352A (zh) * 2010-04-27 2013-01-09 贝林格尔.英格海姆国际有限公司 治疗肿瘤及纤维变性疾病的新组合疗法
WO2015111947A1 (en) * 2014-01-24 2015-07-30 Lg Life Sciences Ltd. Composition for preventing or treating acute lung injury and acute respiratory distress syndrome

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CA2389236A1 (en) 1999-11-02 2001-05-10 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
EP1343782B1 (en) 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2008080153A2 (en) * 2006-12-22 2008-07-03 The Children's Hospital Of Philadelphia A novel protein kinase c therapy for the treatment of acute lung injury
EP3050566B1 (en) 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
CA2753844A1 (en) * 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
JP5823672B2 (ja) 2009-07-27 2015-11-25 国立大学法人 新潟大学 受容体シグナル伝達阻害剤を含む脳梗塞治療用医薬品組成物
EP2640384A1 (en) 2010-11-18 2013-09-25 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
WO2012118632A1 (en) 2011-02-28 2012-09-07 Ning Xi Substituted quinoline compounds and methods of use
EP2699572B1 (en) 2011-04-21 2016-08-10 Origenis GmbH Heterocyclic compounds as kinase inhibitors
CA2852912A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Intellectual Property Limited Pazopanib formulation
BR112014016299A8 (pt) 2011-12-30 2017-07-04 Abbvie Inc imunoglobulinas de domínio variável e usos das mesmas
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP2016530210A (ja) 2013-09-17 2016-09-29 ファーマケア，インク． ヘテロ環式ビニルオートタキシン阻害剤化合物
AU2014324566B2 (en) * 2013-09-30 2019-01-24 The Texas A&M University System Compositions associated with and methods of managing neutrophil movement
WO2015164161A1 (en) * 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
BR112017002466A2 (pt) 2014-08-08 2017-12-05 Forsight Vision4 Inc formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação
JP7108018B2 (ja) 2017-04-17 2022-07-27 イエール ユニバーシティ 急性肺傷害を処置または予防する化合物、組成物および方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142837A1 (en) * 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
CN102869352A (zh) * 2010-04-27 2013-01-09 贝林格尔.英格海姆国际有限公司 治疗肿瘤及纤维变性疾病的新组合疗法
WO2015111947A1 (en) * 2014-01-24 2015-07-30 Lg Life Sciences Ltd. Composition for preventing or treating acute lung injury and acute respiratory distress syndrome

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Effect of Nilotinib on Bleomycin-Induced Acute Lung Injury and Pulmonary Fibrosis in Mice;Chin Kook Rhee et al;《Respiration》;20111231;第82卷;第273-287页，尤其是摘要 *
Siglec-E Promotes _2-Integrin-dependent NADPH Oxidase Activation to Suppress Neutrophil Recruitment to the Lung;Sarah J.McMillan et al;《The Journal of biological chemistry》;20140718;第289卷(第29期);第20370-20376页，尤其是摘要，第20373页左栏讨论，第20375页图5 *

Also Published As

Publication number Publication date
IL270070B2 (en) 2023-09-01
JP7108018B2 (ja) 2022-07-27
WO2018195084A1 (en) 2018-10-25
IL270070A (https=) 2019-12-31
EP3612184B1 (en) 2024-06-05
US12544377B2 (en) 2026-02-10
CN110753546A (zh) 2020-02-04
EP3612184A1 (en) 2020-02-26
US11890283B2 (en) 2024-02-06
US20210121459A1 (en) 2021-04-29
IL270070B1 (en) 2023-05-01
US11166953B2 (en) 2021-11-09
JP2020516689A (ja) 2020-06-11
US20220040177A1 (en) 2022-02-10
US20240165115A1 (en) 2024-05-23
CA3060247A1 (en) 2018-10-25
EP3612184A4 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
CN110753546B (zh) 治疗或预防急性肺损伤的化合物、组合物和方法
Strand et al. Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan‐4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure‐overloaded heart
US20230026808A1 (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
Chen et al. Dependence of fibroblast infiltration in tumor stroma on type IV collagen-initiated integrin signal through induction of platelet-derived growth factor
Trinh et al. Characterization of cysteinyl leukotriene-related receptors and their interactions in a mouse model of asthma
US8252807B2 (en) Methods of inhibiting the interaction between S100 and the receptor for advanced glycation end-products
Gao et al. Interaction of N‐acetyl‐seryl‐aspartyl‐lysyl‐proline with the angiotensin‐converting enzyme 2–angiotensin‐(1–7)–Mas axis attenuates pulmonary fibrosis in silicotic rats
Wang et al. Rosuvastatin attenuates atrial structural remodelling in rats with myocardial infarction through the inhibition of the p38 MAPK signalling pathway
CN108159423B (zh) 治疗和预防心血管疾病的组合物和方法
KR20170036928A (ko) IKKε 억제제를 유효성분으로 함유하는 만성 부비동염 예방 또는 치료용 약학조성물
TW202128212A (zh) 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途
HK40018465A (en) Compounds, compositions and methods of treating or preventing acute lung injury
HK40018465B (zh) 治疗或预防急性肺损伤的化合物、组合物和方法
JP2017109987A (ja) ＥｒｂＢ４＋炎症性マクロファージによって媒介される疾患の治療方法
US11026945B2 (en) Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation
HK40079687A (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
TWI535452B (zh) 使用抗－ｃｄ４４中和抗體來治療和／或預防心房顫動
He A novel prophylactic strategy to minimize stem cell transplantation-related complications
US9801840B1 (en) Pharmaceutical composition and use thereof
RU2663929C2 (ru) Использование производного соединения тиохромено[2,3-с]хинолин-12-она для лечения немелкоклеточного рака легких
Rounds et al. Articles in PresS. Am J Physiol Lung Cell Mol Physiol (March 3, 2017). doi: 10.1152/ajplung. 00393.2016
KR20210111043A (ko) HopQ를 포함하는 암전이 억제용 조성물
Koch The role of MYD88-dependent receptors in the anti-tumor efficacy of the EGFR inhibitor Erlotinib in head and neck cancer
Moayeri et al. Bacillus anthracis Edema Toxin Inhibits Hypoxic Pulmonary Vasoconstriction 1 via Edema Factor and cAMP Mediated Mechanisms in Isolated Perfused Rat Lungs 2 3 Xizhong Cui1, Jeffrey Wang1, Yan Li1, Zoe G. Couse1, Thomas F. Risoleo1, 4 Mahtab Moayeri2, Stephen H. Leppla2, Daniela Malide3, Zu-Xi Yu3, and Peter Q. Eichacker1 5
Nakagawa et al. Combined therapy with mutant-selective EGFR inhibitor and

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40018465

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant